MicroPhage’s mission is to be a worldwide leader in rapid bacterial diagnostics, in both bacterial identification and antibiotic susceptibility / resistance testing, through its bacteriophage-based amplification platform for immunoassay diagnostics. The company will develop, manufacture, and market these tests into the clinical market.

MicroPhage has developed a patented amplification process which can be a "product platform or engine" to create rapid, simple, inexpensive bacterial identification for any industry where bacteria is important to be utilized or needs to be managed.

The company has chosen to focus it's initial efforts to help solve medical crises involving such problems as over use of antibiotics and antibiotic resistant bacteria. Its first products expected in late 2009 are anticipated to set a new standard for clinicians and hospital staff in methicillin-resitant Staphylococcus aureus (MRSA) identification and antibiotic testing.

Additional bacterial pathogens that may be addressed with the company’s technology include:
Vancomycin-resistant Enterococcus (VRE), ESBL-producing Escherichia coli, drug resistant Pseudomonas aeruginosa, and penicillin-resistant Streptococcus pneumoniae.